A picture is worth a thousand words

研报英文原文证据摘录

A picture is worth a thousand words

Update

August 3, 2026 01:18 AM GMT

Morgan Stanley & Co. LLCMBiopharma | North America Terence C Flynn, Ph.D.

Equity Analyst

A picture is worth a thousand Terence.Flynn@morganstanley.comAlexander Yevdokimov, Ph.D. +1 212 761-2230

Research Associate

Alexander.Yevdokimov@morganstanley.com +1 212 761-2167

words Chris Yu, J.D., Ph.D.

Chris.L.Yu@morganstanley.com +1 212 761-2535

Comprehensive US drug market analysis (IQVIA Rx). The latest Hailey Horowitz

weekly Total Prescription YoY growth (wk ending 7/24) was ResearchHailey.Horowitz@morganstanley.comAssociate +1 212 761-5264

+2.0% vs. +1.1% last wk and +1.2% over the past 12 wks. Damien H Kerner

For week ended Jul 24, US total market weekly TRx YoY change was +2.0% vs. Damien.H.Kerner@morganstanley.com +1 212 761-3829

Connor M Massari

+1.7% year ago ( Exhibit10 ). Rolling 4-week TRx YoY was +1.5% and rolling 12-week Equity Analyst

TRx YoY was +1.2%. Extended unit (EUTRx) weekly YoY growth was +1.6%, below Connor.Massari@morganstanley.com +1 212 761-2417

TRx YoY ( Exhibit 13 ). Sequential weekly TRx growth was -0.4% compared to Morgan Stanley India Company Private Limited+

+4.6% week before. Exhibit17 – Exhibit19 depict YoY momentum for key products. Saket Agarwal

BMY's Cobenfy was approved for schizophrenia on 9/26/24. Scripts are ~3,290 for Saket.Agarwal@morganstanley.com +91 22 6995-4012

the week vs ~3,140 last week. For full details on our views on the launch, see our Major Pharmaceuticals

note "Contextualizing Cobenfy launch expectations", where we discuss that the North America

Industry View In-Line

analogs we are most focused on are the schizophrenia volumes from the Rexulti,

Caplyta, and Lybalvi launches. We estimated that to achieve 2026 consensus